12:00 AM
 | 
Sep 05, 2016
 |  BC Week In Review  |  Company News  |  Deals

Boehringer Ingelheim, Amgen deal

Boehringer granted Amgen worldwide rights to develop and commercialize BI 836909 ( AMG 420), a compound in Phase I testing to treat...

Read the full 104 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >